Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$93.13 USD

93.13
25,247,523

+1.13 (1.23%)

Updated Jun 24, 2022 04:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.75%
2Buy18.15%
3Hold9.70%
4Sell5.35%
5Strong Sell2.45%
S&P50010.91%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 37% (157 out of 250)

Industry: Large Cap Pharmaceuticals

Trades from $1

Company Summary

Based in Kenilworth, NJ, Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer, alone accounting for around 40% of its pharmaceutical sales. Keytruda has played an instrumental role in driving Merck’s steady revenue growth in the past few years. Though Keytruda may be Merck’s biggest strength and a solid reason to own the stock, it can also be argued that Merck is excessively dependent on the drug and should look for ways to diversify its product lineup.

Well-known ...

General Information

Merck & Co, Inc

2000 GALLOPING HILL ROAD

KENILWORTH, NJ 07033

Phone: 908-740-4000

Fax: 908-735-1253

Web: http://www.merck.com

Email: investor_relations@merck.com

Industry Large Cap Pharmaceuticals
Sector Medical
Fiscal Year End December
Last Reported Quarter 3/31/2022
Earnings Date

This is a confirmed date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

7/28/2022

EPS Information

Current Quarter EPS Consensus Estimate 1.68
Current Year EPS Consensus Estimate 7.31
Estimated Long-Term EPS Growth Rate 10.10
Earnings Date

This is a confirmed date of earnings release. Neither Zacks Investment Research, Inc. nor its Information Providers can guarantee the accuracy, completeness, timeliness, or correct sequencing of any of the Information on the Web site, including, but not limited to Information originated by Zacks Investment Research, Inc, licensed by Zacks Investment Research, Inc. from Information Providers, or gathered by Zacks Investment Research, Inc. from publicly available sources. There may be delays, omissions, or inaccuracies in the Information.

7/28/2022

Price and Volume Information

Zacks Rank Premium
Yesterday's Close 92.00
52 Week High 94.92
52 Week Low 70.89
Beta 0.36
20 Day Moving Average 11,265,618.00
Target Price Consensus 92.53

MRK

% Price Change
4 Week 0.89
12 Week 13.50
YTD 21.52
% Price Change Relative to S&P 500
4 Week 4.66
12 Week 31.46
YTD 50.73
Share Information
Shares Outstanding (millions) 2,528.80
Market Capitalization (millions) 235,507.59
Short Ratio NA
Last Split Date 2/17/1999
Dividend Information
Dividend Yield 2.96%
Annual Dividend $2.76
Payout Ratio 0.39
Change in Payout Ratio -0.06
Last Dividend Payout / Amount 6/14/2022 / $0.69

Fundamental Ratios

P/E
P/E (F1) 12.75
Trailing 12 Months 13.30
PEG Ratio 1.26
EPS Growth
vs. Previous Year 52.86%
vs. Previous Quarter 18.89%
   
Sales Growth
vs. Previous Year 31.63%
vs. Previous Quarter 17.60%
   
Price Ratios
Price/Book 5.75
Price/Cash Flow 12.73
Price / Sales 4.36
ROE
3/31/22 47.86
12/31/21 47.24
9/30/21 48.21
ROA
3/31/22 17.92
12/31/21 16.70
9/30/21 16.00
Current Ratio
3/31/22 1.40
12/31/21 1.27
9/30/21 1.31
Quick Ratio
3/31/22 1.14
12/31/21 1.02
9/30/21 1.07
Operating Margin
3/31/22 32.91
12/31/21 31.68
9/30/21 29.84
Net Margin
3/31/22 26.27
12/31/21 26.02
9/30/21 14.64
Pre-Tax Margin
3/31/22 29.18
12/31/21 28.50
9/30/21 13.32
Book Value
3/31/22 16.20
12/31/21 15.14
9/30/21 14.17
Inventory Turnover
3/31/22 2.77
12/31/21 2.32
9/30/21 2.48
Debt-to-Equity
3/31/22 0.75
12/31/21 0.80
9/30/21 0.64
Debt to Capital
3/31/22 42.75
12/31/21 44.51
9/30/21 38.98